Group items matching

in title, tags, annotations or url

Struggling with osteoarthritis pain? Discover the revolutionary benefits of Stem Cell Therapy and regain your mobility!

Are you or a loved one struggling with muscular dystrophy? Discover the groundbreaking benefits of stem cell therapy in India!

Are you or a loved one battling Parkinson's Disease? Traditional treatments often focus only on managing symptoms, but there's a revolutionary approach offering a new ray of hope - Stem Cell Therapy!

Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison.

Graft-versus-host disease (GvHD) is a systemic disorder and a common complication after allogeneic hematopoietic stem cell transplant. The condition can be subclassified into acute classic GVHD, persistent, recurrent, or late-onset acute GVHD, classic chronic GVHD, and overlap syndrome. High adoption of hematopoietic stem cell transplantation and increasing prevalence of certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia is expected to propel growth of the graft versus host disease (GvHD) market. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. Moreover, around 30,000 patients undergo allogeneic hematopoietic stem cell transplant annually in the United States, with approximately 20% to 85% developing aGvHD that affects the skin, gut, or liver. Increasing number of clinical trials for graft versus host disease is expected to offer lucrative growth opportunities for players in the graft versus host disease (GvHD) market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/high-adoption-of-hematopoietic-stem.html

Are you or a loved one battling Multiple Sclerosis? Explore the groundbreaking potential of stem cell therapy in India!

Laboratory centrifuge equipment is used to separate materials from the liquid medium into which they dissolve, depending on their shape, size, density, and viscosity. It works on the principle of centrifugation. A centrifuge is a device that uses centrifugal force to separate various components of a fluid. It is also used to separate cellular elements such as red blood cell (RBC) and white blood cell (WBC) from a blood sample, remove protein precipitate from analytical sample, separate solid or semisolid precipitant from the analytical sample, and isolate macromolecules such as RNA, DNA, and lipids from the cell. Laboratory centrifuge equipment is widely used to conduct a diversity of laboratory work, and thus, there is a growing demand for reliable, durable, and multifunctional laboratory centrifuge equipment. With increasing diagnostics and research and development activities, the demand for such equipment is also increasing. According to the World Health Organization (WHO), in 2018, noncommunicable diseases (chronic diseases), such as diabetes, cancer, and heart disease, kill around 41 million people each year, equivalent to 71% of all deaths worldwide. Non-transmissible chronic disease is the most pressing health problem in Mexico in recent decades. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/03/laboratory-centrifuge-equipment-used-to.html

Advanced Therapy Medicinal Products (ATMPs) offer a real and tangible hope for many different chronic illnesses for which there currently are no or limited therapeutic options. The science and technology that support these products are developing rapidly and therefore the products that are on the market today will undoubtedly continue to improve and grow in effectiveness and capability over time. Patients around the world are now beginning to experience the benefits of these improved products. One such product is Stem Cell Therapy, which uses stem Cells from healthy Cells taken from the patient's own body. High prevalence of Alzheimer's disease is expected to propel growth of the advanced therapy medicinal products market. For instance, According to the data from Alzheimer's Association, around 5.7 million people in the U.S. were suffering from Alzheimer's disease in 2018. Moreover, increasing adoption of gene therapy is also expected to aid in growth of the market. For instance, in March 2020, AVROBIO, Inc., a clinical-stage gene therapy company, announced that a second patient in the AVR-RD-04 Phase 1/2 clinical trial in cystinosis has been enrolled and has completed apheresis. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/high-prevalence-of-alzheimers-disease.html